Bone morphogenetic protein signaling regulation of AMPK and PI3K in lung cancer cells and C. elegans.
AMPK
Akt
BMP
BMPR2
LKB1
Lung cancer
Metabolism
PIK3
mTOR
Journal
Cell & bioscience
ISSN: 2045-3701
Titre abrégé: Cell Biosci
Pays: England
ID NLM: 101561195
Informations de publication
Date de publication:
31 May 2022
31 May 2022
Historique:
received:
25
10
2021
accepted:
17
05
2022
entrez:
1
6
2022
pubmed:
2
6
2022
medline:
2
6
2022
Statut:
epublish
Résumé
Bone morphogenetic protein (BMP) is a phylogenetically conserved signaling pathway required for development that is aberrantly expressed in several age-related diseases including cancer, Alzheimer's disease, obesity, and cardiovascular disease. Aberrant BMP signaling in mice leads to obesity, suggesting it may alter normal metabolism. The role of BMP signaling regulating cancer metabolism is not known. To examine BMP regulation of metabolism, C. elegans harboring BMP gain-of-function (gof) and loss-of-function (lof) mutations were examined for changes in activity of catabolic and anabolic metabolism utilizing Western blot analysis and fluorescent reporters. AMP activated kinase (AMPK) gof and lof mutants were used to examine AMPK regulation of BMP signaling. H1299 (LKB1 wild-type), A549 (LKB1 lof), and A549-LKB1 (LKB1 restored) lung cancer cell lines were used to study BMP regulation of catabolic and anabolic metabolism. Studies were done using recombinant BMP ligands to activate BMP signaling, and BMP receptor specific inhibitors and siRNA to inhibit signaling. BMP signaling in both C. elegans and cancer cells is responsive to nutrient conditions. In both C. elegans and lung cancer cell lines BMP suppressed AMPK, the master regulator of catabolism, while activating PI3K, a regulator of anabolism. In lung cancer cells, inhibition of BMP signaling by siRNA or small molecules increased AMPK activity, and this increase was mediated by activation of LKB1. BMP2 ligand suppressed AMPK activation during starvation. BMP2 ligand decreased expression of TCA cycle intermediates and non-essential amino acids in H1299 cells. Furthermore, we show that BMP activation of PI3K is mediated through BMP type II receptor. We also observed feedback signaling, as AMPK suppressed BMP signaling, whereas PI3K increased BMP signaling. These studies show that BMP signaling suppresses catabolic metabolism and stimulates anabolic metabolism. We identified feedback mechanisms where catabolic induced signaling mediated by AMPK negatively regulates BMP signaling, whereas anabolic signaling produces a positive feedback regulation of BMP signing through Akt. These mechanisms were conserved in both lung cancer cells and C. elegans. These studies suggest that aberrant BMP signaling causes dysregulation of metabolism that is a potential mechanism by which BMP promotes survival of cancer cells.
Sections du résumé
BACKGROUND
BACKGROUND
Bone morphogenetic protein (BMP) is a phylogenetically conserved signaling pathway required for development that is aberrantly expressed in several age-related diseases including cancer, Alzheimer's disease, obesity, and cardiovascular disease. Aberrant BMP signaling in mice leads to obesity, suggesting it may alter normal metabolism. The role of BMP signaling regulating cancer metabolism is not known.
METHODS
METHODS
To examine BMP regulation of metabolism, C. elegans harboring BMP gain-of-function (gof) and loss-of-function (lof) mutations were examined for changes in activity of catabolic and anabolic metabolism utilizing Western blot analysis and fluorescent reporters. AMP activated kinase (AMPK) gof and lof mutants were used to examine AMPK regulation of BMP signaling. H1299 (LKB1 wild-type), A549 (LKB1 lof), and A549-LKB1 (LKB1 restored) lung cancer cell lines were used to study BMP regulation of catabolic and anabolic metabolism. Studies were done using recombinant BMP ligands to activate BMP signaling, and BMP receptor specific inhibitors and siRNA to inhibit signaling.
RESULTS
RESULTS
BMP signaling in both C. elegans and cancer cells is responsive to nutrient conditions. In both C. elegans and lung cancer cell lines BMP suppressed AMPK, the master regulator of catabolism, while activating PI3K, a regulator of anabolism. In lung cancer cells, inhibition of BMP signaling by siRNA or small molecules increased AMPK activity, and this increase was mediated by activation of LKB1. BMP2 ligand suppressed AMPK activation during starvation. BMP2 ligand decreased expression of TCA cycle intermediates and non-essential amino acids in H1299 cells. Furthermore, we show that BMP activation of PI3K is mediated through BMP type II receptor. We also observed feedback signaling, as AMPK suppressed BMP signaling, whereas PI3K increased BMP signaling.
CONCLUSION
CONCLUSIONS
These studies show that BMP signaling suppresses catabolic metabolism and stimulates anabolic metabolism. We identified feedback mechanisms where catabolic induced signaling mediated by AMPK negatively regulates BMP signaling, whereas anabolic signaling produces a positive feedback regulation of BMP signing through Akt. These mechanisms were conserved in both lung cancer cells and C. elegans. These studies suggest that aberrant BMP signaling causes dysregulation of metabolism that is a potential mechanism by which BMP promotes survival of cancer cells.
Identifiants
pubmed: 35641992
doi: 10.1186/s13578-022-00817-3
pii: 10.1186/s13578-022-00817-3
pmc: PMC9153151
doi:
Types de publication
Journal Article
Langues
eng
Pagination
76Subventions
Organisme : NIA NIH HHS
ID : R21 AG075315
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA225830
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM101972
Pays : United States
Organisme : NIH HHS
ID : R01CA225830
Pays : United States
Organisme : NIH HHS
ID : R01CA225830-S2
Pays : United States
Informations de copyright
© 2022. The Author(s).
Références
Exp Mol Med. 2016 Jul 15;48(7):e245
pubmed: 27416781
Cell Commun Signal. 2019 Nov 19;17(1):150
pubmed: 31744505
Cytokine Growth Factor Rev. 2009 Oct-Dec;20(5-6):367-77
pubmed: 19926516
Aging Cell. 2018 Jun;17(3):e12743
pubmed: 29508513
Mol Cancer Res. 2004 Mar;2(3):141-9
pubmed: 15037653
PLoS One. 2011;6(9):e24152
pubmed: 21931657
Semin Hematol. 2013 Jul;50(3):232-8
pubmed: 23953340
Proc Natl Acad Sci U S A. 2014 Feb 18;111(7):2578-83
pubmed: 24550286
Front Biosci (Landmark Ed). 2011 Jan 01;16(3):865-97
pubmed: 21196208
Neural Dev. 2012 May 04;7:16
pubmed: 22559862
PLoS One. 2011 Feb 02;6(2):e16155
pubmed: 21311592
Anal Chem. 2010 Dec 1;82(23):9818-26
pubmed: 21049934
J Exp Bot. 2016 Jun;67(13):3897-907
pubmed: 27270999
Cell. 2015 Feb 26;160(5):842-855
pubmed: 25723162
PLoS One. 2009 Oct 20;4(10):e7506
pubmed: 19841742
Obes Rev. 2019 May;20(5):648-658
pubmed: 30609449
Bone Res. 2015 Apr 14;3:15005
pubmed: 26273537
EMBO J. 1999 Jan 4;18(1):179-87
pubmed: 9878061
Mol Cancer. 2016 Apr 06;15:27
pubmed: 27048361
Biochem Soc Trans. 2016 Aug 15;44(4):1117-34
pubmed: 27528760
PLoS Genet. 2013 Aug;9(8):e1003737
pubmed: 24009527
Arterioscler Thromb Vasc Biol. 2012 Mar;32(3):613-22
pubmed: 22223731
Stem Cells. 2015 May;33(5):1577-88
pubmed: 25538007
J Neurosci. 2010 Sep 15;30(37):12252-62
pubmed: 20844121
iScience. 2018 Nov 30;9:1-13
pubmed: 30368077
Exp Mol Med. 2020 Jan;52(1):15-30
pubmed: 31980738
Neurobiol Aging. 2016 Feb;38:164-175
pubmed: 26827654
BMC Dev Biol. 2010 Jun 07;10:61
pubmed: 20529267
Mol Metab. 2019 Jul;25:50-63
pubmed: 31027994
Carcinogenesis. 2003 Sep;24(9):1445-54
pubmed: 12819188
J Biol Chem. 2011 Jan 7;286(1):341-53
pubmed: 20974850
Mol Cancer Res. 2005 Dec;3(12):679-84
pubmed: 16380505
J Biol Chem. 2008 May 30;283(22):14988-93
pubmed: 18408008
Genes Dev. 2011 Mar 1;25(5):460-70
pubmed: 21317241
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Genes Dev. 2019 Feb 1;33(3-4):150-165
pubmed: 30692209
Genes Immun. 2020 Nov;21(5):301-310
pubmed: 32770079
Int J Biol Sci. 2018 Aug 6;14(11):1483-1496
pubmed: 30263000
Genetics. 1995 Dec;141(4):1399-406
pubmed: 8601482
Proc Natl Acad Sci U S A. 2018 Nov 6;115(45):11625-11630
pubmed: 30352848
Ann Thorac Surg. 2005 Sep;80(3):1028-32
pubmed: 16122479
Mol Cell. 2017 Jun 15;66(6):789-800
pubmed: 28622524
Mol Biol Cell. 2019 Dec 15;30(26):3151-3160
pubmed: 31693440
J Biol Chem. 2021 Jan-Jun;296:100037
pubmed: 33158991
Cell Metab. 2014 Jul 1;20(1):10-25
pubmed: 24726383
WormBook. 2006 Feb 11;:1-11
pubmed: 18050451
BMC Biol. 2014 May 30;12:43
pubmed: 24885555
Mol Cancer. 2013 Oct 26;12(1):129
pubmed: 24160469
ACS Chem Biol. 2010 Feb 19;5(2):245-53
pubmed: 20020776
Sci Rep. 2019 Feb 28;9(1):3136
pubmed: 30816280
Mol Cell. 2020 Oct 15;80(2):263-278.e7
pubmed: 33022274
Genetics. 1974 May;77(1):71-94
pubmed: 4366476
J Ovarian Res. 2009 Apr 14;2:4
pubmed: 19366455
Genes Cells. 2002 Sep;7(9):949-60
pubmed: 12296825
J Biol Chem. 2002 Feb 15;277(7):4883-91
pubmed: 11729207
Oncogene. 2018 Jul;37(27):3672-3685
pubmed: 29622797
PLoS One. 2012;7(8):e41460
pubmed: 22916109
Biochim Biophys Acta. 2009 Dec;1793(12):1819-27
pubmed: 19782107
Cell Commun Signal. 2021 Sep 25;19(1):97
pubmed: 34563224
Cold Spring Harb Perspect Biol. 2017 Jun 1;9(6):
pubmed: 28096268
Mol Cell Biol. 2013 Jun;33(12):2413-24
pubmed: 23572558
Pathol Oncol Res. 2011 Jun;17(2):257-61
pubmed: 20848249
Oncogene. 2006 Feb 2;25(5):685-92
pubmed: 16247476
Oncotarget. 2016 Jan 12;7(2):1120-43
pubmed: 26701726
Nat Immunol. 2009 Mar;10(3):249-56
pubmed: 19198592
Brain Res. 2003 Dec 19;994(1):81-90
pubmed: 14642451
PLoS One. 2010 Jan 18;5(1):e8758
pubmed: 20090912